Results for Neratinib Plus Capecitabine in HER2+ Breast Cancer Brain Metastases

Video

Rachel A. Freedman, MD, MPH, discusses a phase II trial of neratinib plus capecitabine for patients with HER2-positive breast cancer brain metastases.

Newsletter

Stay up to date on practice-changing data in community practice.

Recent Videos